drugset / Trial / NCT07336446
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
RandomizedSequentialOpen-labelTreatment
Summary
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.
Timeline
- Start
- 2026-01-27
- Primary completion
- 2026-11-05
- Completion
- 2026-11-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD9750 | Unknown | — | — |
| Subject | Saruparib | Small molecule | — | — |